Key Business Updates and Management Commentary

Industry Context and Challenges:

  • Management discussed significant industry challenges stemming from the implementation of ALMM-2 (Approved List of Models and Manufacturers) policy, which was implemented "in anticipation of capacity to come up" but faced timing issues.
  • The Indian solar industry "struggled in last 3 months" due to these policy changes and supply chain disruptions caused by geopolitical situations.
  • Despite short-term challenges, management expressed strong long-term optimism for India's solar journey, expecting it to "increase by three times in days to come" with implementation of national green grid, BESS, and other initiatives.

Current Operations and Order Book:

  • The company confirmed it is "back to our 24/7 operations" after facing challenges in the previous 3 months.
  • Utilization of installed capacity is "much higher" currently.
  • Order book remains "intact" and the company expects to "cover up in coming 4.5 months for whatever the revenue guidance that we have given."
  • Supply chain issues that were "disturbed because of the geopolitical situation" are now "in order."

Cell Line Project Update:

  • The TOPCon cell line project faced challenges related to land, Pollution Control, and EC clearance, but these have been "cleared."
  • The company expects "very soon you will hear the news for the ground-breaking for the cell line."
  • Technology challenges have been addressed with "Plan A, B and C" and the company is "in discussion with all the equipment suppliers."
  • Project remains on track for execution by December 2027.
  • Capex for the cell line is estimated at "INR500 crores to INR600 crores per gigawatt" including land and building.

Financial Performance and Guidance:

  • Management acknowledged that FY27 has been "challenging" particularly from May 2026 onward, which will impact PAT margins compared to previous levels.
  • The company expects to recover revenue, EBITDA margin, and PAT margin through execution of order book in the remaining 4.5 months.
  • For FY29, management provided guidance of EBITDA margins in the "range of 23% to 25%" with PAT margins of "12% to 14%" and revenues "somewhere about in the range of INR4,000 crores."

Product and Technology Developments:

  • Tapi RQ Quarter Cell Module: Recently introduced technology currently working on certification. Converting existing production lines to make them compatible. Expected to help "save a lot of cost on BOS" with similar margins to TOPCon G12R modules if productivity remains same.
  • TOPCon Technology: Believed to be the long-term technology for India with potential transition to tandem perovskite technology in future.
  • Rear Contract Technology: Collaboration with ISC Konstanz to develop Rear Contract technology, with arrangements for them to help set up and operate the upcoming cell line.
  • Warranty Provisions: No warranty claims experienced to date. Most supplies insured by Munich Re for 30-year warranty coverage, with premiums paid by Solex.

Manufacturing and Expansion Plans:

  • BESS Assembly Line: Planning INR250 crores capex for BESS assembly line with target to start by September 2027.
  • US Manufacturing: Evaluating manufacturing possibilities in US market, studying operational costs and feasibility. Considering US as "worth looking at in terms of manufacturing" that could provide "high return."
  • Gujarat Investment: INR4,000 crores MOU with Government of Gujarat for 5 GW solar cell and 10 GW BESS assembly is "in line."
  • Long-term Vision: $1 billion investment roadmap with INR4,500 crores as first phase in Gujarat, followed by wafer capacity expansion and battery cell manufacturing.

Market and Customer Information:

  • Supplied 200 MW to Welspun and Zelestra under arrangement with LONGi (produced to LONGi standards under their supervision but with Solex brand name).
  • Currently exporting to Middle East, Africa, and Europe regularly. Previously tried small consignment to US but paused due to tariffs. Now re-evaluating US market focus.
  • Majority of current supply uses non-DCR modules with imported cells. Have tie-ups with domestic cell suppliers for future DCR requirements.

Funding Strategy:

  • Recently signed term sheet for INR50 crores CCD in subsidiary for cell line funding.
  • Using structured debt initially due to current valuation concerns, with plans to convert to equity later when valuations improve.
  • Taking cautious approach to fundraising to avoid excessive equity dilution.

Industry Perspectives:

  • Disagreed with notion of industry overcapacity, explaining that while nameplate capacity is 230 GW, actual utilization is ~50% and TOPCon capacity is only 75-80 GW against 60 GW demand last year.
  • Expecting industry consolidation in coming months.
  • Expressed optimism about future of solar industry in India despite current challenges.

Forward-Looking Statements

The call included forward-looking statements involving risks and uncertainties related to future financial and operating performance.